AAD  Vol.3 No.1 , March 2014
Mutations of TP53 Gene and Oxidative Stress in Alzheimer’s Disease Patients
Abstract: Alzheimer’s disease (AD) leads to the generation of β-amyloid (Aβ), which may damage DNA and thus lead to apoptosis induction by the p53 pathway. Dysfunction of the p53 protein may then be connected with the development of AD. Studies were conducted on 28 AD patients and 30 non-AD controls. Analysis of TP53 mutations in exon 7 was performed on DNA isolated from whole blood and biochemical parameters in the peripheral lymphocytes of these individuals. Our study showed a silent mutation TP53 C708T (21%) [p < 0.05] and a missense mutation TP53 C748A (4%) only in the AD patients. Moreover, in AD patients with the TP53 C748A mutation, the level of 8-oxo-2’- deoxyguanosine (8-oxo2dG) was more than 5 times higher than the average level in this study group. In AD patients with the wild-type TP53 gene, the level of 8-oxo2dG was correlated with the level of protein p53 (R = +0.7388, p < 0.05). The level of the oxoguanine DNA glycosylase 1 (OGG1) protein was similar in AD patients with the silent mutation and the wild-type gene TP53 (p < 0.05) and lower than in the controls. It appears that mutations in exon 7 of TP53 (C748A, C708T) may be associated with pathogenesis of AD.
Cite this paper: Dorszewska, J. , Różycka, A. , Oczkowska, A. , Florczak-Wyspiańska, J. , Prendecki, M. , Dezor, M. , Postrach, I. , Jagodzinski, P. and Kozubski, W. (2014) Mutations of TP53 Gene and Oxidative Stress in Alzheimer’s Disease Patients. Advances in Alzheimer's Disease, 3, 24-32. doi: 10.4236/aad.2014.31004.

[1]   Hardy, J. and Selkoe, D.J. (2002) The amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics. Science, 297, 353-356.

[2]   Armstrong, R.A. (2009) The Molecular Biology of Senile Plaques and Neurofibrillary Tangles in Alzheimer’s Disease. Folia Neuropathologica, 47, 289-299.

[3]   Armstrong, R.A. (2010) A Spatial Pattern Analysis of Beta-Amyloid (Abeta) Deposition in the Temporal Lobe in Alz- heimer’s Disease. Folia Neuropathologica, 48, 67-74.

[4]   Parks, J.K., Smith, T.S., Trimmer, P.A., Bennett, J.P. and Parker, W.D. (2001) Neurotoxic Abeta Peptides Increase Oxidative Stress in Vivo through NMDA-Receptor and Nitric-Oxide-Synthase Mechanisms, and Inhibit Complex IV Activity and Induce a Mitochondrial Permeability Transition in Vitro. Journal of Neurochemistry, 76, 1050-1056.

[5]   Pluta, R., Ulamek, M. and Jabloński, M., (2010) Consideration of the Ischaemic Basis and Treatment of Alzheimer’s Disease. Folia Neuropathologica, 48, 11-26.

[6]   Wang, J., Xiong, S., Xie, C., Markesbery, W.R. and Lovell, M.A. (2005) Increased Oxidative Damage in Nuclear and Mitochon drial DNA in Alzheimer’s Disease. Journal of Neurochemistry, 93, 953-962.

[7]   Wang, J., Markesbery, W.R. and Lovell, M.A., (2006) Increased Oxidative Damage in Nuclear and Mitochondrial DNA in Mild Cognitive Impairment. Journal of Neurochemistry, 96, 825-832.

[8]   Dorszewska, J., Florczak, J., Rózycka, A., Jaroszewska-Kolecka, J., Trzeciak, W.H. and Kozubski, W. (2005) Polymorphisms of the CHRNA4 Gene Encoding the Alpha4 Subunit of Nicotinic Acetylcholine Receptor as Related to the Oxidative DNA Damage and the Level of Apoptotic Proteins in Lymphocytes of the Patients with Alzheimer’s Disease. DNA and Cell Biology, 24, 786-794.

[9]   Dorszewska, J., Kempisty, B., Jaroszewska-Kolecka, J., Rózycka, A., Florczak, J., Lianeri, M., Jagodzinski, P.P. and Kozubski, W. (2009) Expression and Polymorphisms of Gene 8-Oxoguanine Glycosylase 1 and the Level of Oxidative DNA Damage in Peripheral Blood Lymphocytes of Patients with Alzheimer’s Disease. DNA and Cell Biology, 28, 579-588.

[10]   Hirano, T. (2008) Repair System of 7, 8-Didydro-8-Oxoguanine as a Defense Line against Carcinogenesis. Journal of Radiation Research, 49, 329-340.

[11]   De la Monte, S.M. and Wands, J.R. (2006) Molecular Indices of Oxidative Stress and Mitochondrial Dysfunction Occur Early and Often Progress with Severity of Alzheimer’s Disease. Journal of Alzheimer’s Disease, 9, 167-181.

[12]   Frain, L., Driver, J., Gaziano, J.M., Lu, K.P., Kowall, N., Gagnon, D., Cho, K., Betensky, R. and Swanson, D. (2013) A Reduced Risk of Alzheimer Disease Is Associated with the Majority of Cancers in a National Cohort of Veterans. Alzheimer’s Association International Conference, Boston, 13-18 July 2013, 3-175.

[13]   Lanni, C., Racchi, M., Memo, M., Govoni, S. and Uberti, D. (2012) p53 at the Crossroads between Cancer and Neurodegeneration. Free Radical Biology & Medicine, 52, 1727-1733.

[14]   McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D. and Stadlan, E.M. (1984) Clinical Diagnosis of Alzheimer’s Disease: Report of the NINCDS-ADRDA Work Group under the Auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology, 34, 939-944.

[15]   Olsen, A., Siboska, G.E., Clark, B.F. and Rattan, S.I. (1999) N6-Furfuryladenine, Kinetin, Protects against Fenton Reaction-Mediated Oxidative Damage to DNA. Biochemical and Biophysical Research Communications, 265, 499-502.

[16]   Ohnishi, T., Inoue, N., Matsumoto, H., Omatsu, T., Ohira, Y., Nagaoko, S. (1996) Cellular Content of p53 Protein in rat Skin after Exposure to the Space Environment. Journal of Applied Physiology, 81, 183-185.

[17]   Dezor, M., Dorszewska, J., Florczak, J., Kempisty, B., Jaroszewska-Kolecka, J., Rózycka, A., Pólrolniczak, A., Bugaj, R., Jagodziński, P.P. and Kozubski, W. (2011) Expression of 8-Oxoguanine DNA Glycosylase 1 (OGG1) and the Level of p53 and TNF-Alpha Proteins in Peripheral Lymphocytes of Patients with Alzheimer’s Disease. Folia Neuropathologica, 49, 123-131.

[18]   Pastorcic, M. and Das, H.L., (2000) Regulation of Transcription of the Human Presenilin-1 Gene by Ets Transcription Factors and the p53 Protooncogene. The Journal of Biological Chemistry, 275, 34938-34945.

[19]   Kang, J., Lemaire, H.G., Unterbeck, A., Salbaum, J.M., Masters, C.L., Grzeschik, K.H., Multhaup, G., Beyreuther, K. and Müller-Hill, B. (1987) The Precursor of Alzheimer’s Disease Am-yloid A4 protein Resembles a Cell-Surface Receptor. Nature, 325, 733-736.

[20]   Matsuoka, Y., Picciano, M., Malester, B., LaFrancois, J., Zehr, C., Daeschner, J.M., Olschowka, J.A., Fonseca, M.I., O’Banion, M.K., Tenner, A.J, Lemere, C.A. and Duff, K. (2001) Inflammatory Responses to Amyloidosis in a Transgenic Mouse Model of Alzheimer’s Disease. The American Journal of Pathology, 158, 1345-1354.

[21]   Citron, M., Oltersdorf, T., Haass, C., McConlogue, L., McConlogue, L., Hung, A.Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I. and Selkoe, D.J. (1992) Mutation of the Beta-Amyloid Precursor Protein in Familial Alzheimer’s Disease Increases Beta-Protein Production. Nature, 360, 672-674.

[22]   Busciglio, J., Pelsman, A., Wong, C., Pigino, G., Yuan, M., Mori, H. and Yankner, B.A. (2002) Altered Metabolism of the Amyloid Beta Precursor Protein Is Associated with Mitochondrial Dysfunction in Down’s Syndrome. Neuron, 33, 677-688.

[23]   Glabe, C. (2001) Intracellular Mechanisms of Amyloid Accumulation and Pathogenesis in Alzheimer’s Disease. Journal of Molecular Neuroscience, 17, 137-145.

[24]   Shie, F.S., LeBoeuf, R.C. and Jin, L.W. (2003) Early Intraneuronal Abeta Deposition in the Hippocampus of APP Transgenic mice. Neuroreport, 14, 123-129.

[25]   Takahashi, R.H., Milner, T.A., Li, F., Nam, E.E., Edgar, M.A., Yamaguchi, H., Beal, M.F., Xu, H., Greengard, P. and Gouras, G.K. (2002) Intraneuronal Alzheimer Abeta42 Accumulates in Multivesicular Bodies and Is Associated with Synaptic Pathology. The American Journal of Pathology, 161, 1869-1879.

[26]   Ohyagi, Y., Asahara, H., Chui, D.H., Tsuruta, Y., Sakae, N., Miyoshi, K., Yamada, T., Kikuchi, H., Taniwaki, T., Murai, H., Ikezoe, K., Furuya, H., Kawarabayashi, T., Shoji, M., Checler, F., Iwaki, T., Makifuchi, T.T., Takeda, K., Kira, J. and Tabira, T. (2005) Intracellular Abeta42 Activates p53 Promoter: A Pathway to Neurodegeneration in Alzheimer’s Disease. The FASEB Journal, 19, 255-257.

[27]   Dorszewska, J., Florczak, J., Rózycka, A., Kempisty, B., Jaroszewska-Kolecka, J., Chojnicka, K., Trzeciak, W.H. and Kozubski, W. (2007) Oxidative DNA Damage and Level of Thiols as Related to Polymorphisms of MTHFR, MTR, MTHFD1 in Alzheimer’s and Parkinson’s Diseases. Acta Neurobiolgiae Experimentalis, 67, 113-129.

[28]   Migliore, L., Fontana, I., Trippi, F., Colognato, R., Coppede, F., Tognoni, B., Nucciarone, B. and Siciliano, G. (2005) Oxidative DNA Damage in Peripheral Leukocytes of Mild Cognitive Impairment and AD Patients. Neurobiology of Aging, 26, 567-573.

[29]   Dorszewska, J., Oczkowska. A., Florczak, J., Dezor, M. and Kozubski, W. (2013) Mutations of TP53 C708T and C748A, Oxidative DNA Damage, and p53 and OGG1 Protein Levels in Peripheral Lymphocytes of the People with Alzheimer’s Disease. Alzheimer’s & Dementia, 9, Supp., 567, Alzheimer’s Association International Conference, Boston, 13-18 July 2013, 3-044.

[30]   Iida, T., Furuta, A., Nishioka, K., Nakabeppu, Y. and Iwaki, T. (2002) Expression of 8-Oxoguanine DNA Glycosylase Is Reduced and Associated with Neurofibrillary Tangles in Alzheimer’s Disease Brain. Acta Neuropathologica, 103, 20-25.

[31]   Mao, G., Pan, X., Zhu, B.B., Zhang, Y., Yuan, F., Huang, J., Lovell, M.A., Lee, M.P., Markesbery, W.R., Li, G.M. and Gu, L. (2007) Identification and Characterization of OGG1 Mutations in Patients with Alzheimer’s Disease. Nucleic Acids Research, 35, 2759-2766.

[32]   Bougeard, G., Brugieres, L., Chompret, A., Gesta, P., Charbonnier, F., Valent, A., Martin, C., Raux, G., Feunteun, J., Bressac-de Paillerets, B. and Frébourg, T. (2003) Screening for TP53 Rearrangements in Families with the Li-Fraumeni Syndrome Reveals a Complete Deletion of the TP53 Gene. Oncogene, 22, 840-846.

[33]   Gavino, C. and Richard, S. (2011) Loss of p53 in Quaking Viable Mice Leads to Purkinje Cell Defects and Reduced Survival. Scientific Reports, 1, 84.

[34]   Hollstein, M., Sidransky, D., Vogelstein, B. and Harris, C.C. (1991) p53 Mutations in Human Cancers. Science, 253, 49-53.

[35]   Nigro, J.M., Baker, S.J., Preisinger, A.C., Jessup, J.M., Hostetter, R., Cleary, K., Bigner, S.H., Davidson, N., Baylin, S. and Devilee, P. (1989) Mutations in the p53 Gene Occur in Diverse Human Tumour Types. Nature, 342, 705-708.

[36]   Watanabe, K., Sato, K., Biernat, W., Tachibana, O., von Ammon, K., Ogata, N., Yonekawa, Y., Kleihues, P. and Ohgaki, H. (1997) Incidence and Timing of p53 Mutations during Astrocytoma Progression in Patients with Multiple Biopsies. Clinical Cancer Research, 3, 523-530.

[37]   Reilly, K.M., Loisel, D.A., Bronson, R.T., McLaughlin, M.E. and Jacks, T. (2000) Nf1;Trp53 Mutant Mice Develop Glioblastoma with Evidence of Strain-Specific Effects. Nature Genetics, 26, 109-113.

[38]   Zhang, R., Takahashi, S., Orita, S., Yoshida, A., Maruyama, H., Shirai, T. and Ohta, N. (1998) p53 Gene Mutations in Rectal Cancer Associated with Schistosomiasis Japonica in Chinese Patients. Cancer Letters, 131, 215-221.

[39]   Boersma, B.J., Howe, T.M., Goodman, J.E., Yfantis, H.G., Lee, D.H., Chanock, S.J. and Ambs, S. (2006) Association of Breast Cancer Outcome with Status of p53 and MDM2 SNP309. Journal of the National Cancer Institute, 98, 911-919.

[40]   Waldmann, J., Patsalis, N., Fendrich, V., Langer, P., Saeger, W., Chaloupka, B., Ramaswamy, A., Fassnacht, M., Bartsch, D.K. and Slater, E.P. (2012) Clinical Impact of TP53 Alterations in Adrenocortical Carcinomas. Langenbeck’s Archives of Surgery, 397, 209-216.

[41]   Sakamoto, Y., Kato, S., Takahashi, M., Okada, Y., Yasuda, K., Watanabe, G., Imai, H., Sato, A. and Ishioka, C. (2011) Contribution of Autophagic Cell Death to p53-Dependent Cell Death in Human Glioblastoma Cell Line SF126. Cancer Science, 102, 799-807.

[42]   Alves da Costa, C., Paitel, E., Mattson, M.P., Amson, R., Telerman, A., Ancolio, K. and Checler, F. (2002) Wild-Type and Mutated Presenilins 2 Trigger p53-Dependent Apoptosis and Down-Regulate Presenilin 1 Expression in HEK293 Human Cells and in Murine Neurons. Proceedings of the National Academy of Sciences of the United States of America, 99, 4043-4048.

[43]   Das, H.K., Tchedre, K. and Mueller, B. (2012) Repression of Transcription of Presenilin-1 Inhibits γ-Secretase Independent ER Ca(2+) Leak that Is Impaired by FAD Mutations. Journal of Neurochemistry, 122, 487-500.

[44]   Wang, X., Wang, W., Li, L., Perry, G., Lee, H.G. and Zhu, X.W. (2013) Oxidative Stress and Mitochondrial Dysfunction in Alzheimer’s Disease. Biochimica et Biophysica Acta, in press.

[45]   Uberti, D., Lanni, C., Carsana, T., Francisconi, S., Missale, C., Racchi, M., Govoni, S. and Memo, M. (2006) Identification of a Mutant-Like Conformation of p53 in Fibroblasts from Sporadic Alzheimer’s Disease Patients. Neurobiology of Aging, 27, 1193-1201.